PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Latin American Real-world Study in Acute Leukemia
- Conditions
- Acute Lymphoid LeukemiaAcute Myeloid Leukemia
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 589
- Registration Number
- NCT05166135
- Locations
- 🇧🇷
Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil
🇨🇱Hospital Guillermo Grant Benavente, Concepcion, Chile
🇦🇷Hospital Italiano de La Plata, La Plata, Buenos Aires, Argentina
Crizotinib Continuation Clinical Study
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT05160922
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Fujian Province Oncology Hospital, Fuzhou, Fujian, China
Patient Reported Health-Related Quality of Life Associated With COVID-19
- Conditions
- COVID-19Coronavirus Disease 2019Influenza
- Interventions
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 999
- Registration Number
- NCT05160636
- Locations
- 🇺🇸
CVS Health, Woonsocket, Rhode Island, United States
Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 34
- Registration Number
- NCT05158244
- Locations
- 🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 640
- Registration Number
- NCT05156398
- Locations
- 🇵🇱
Wojewodzki Specjalistyczny Szpital Dzieciecy, Krakow, Malopolskie, Poland
🇺🇸Diamond Headache Clinic, Chicago, Illinois, United States
🇺🇸The Belinga Clinic, Fort Smith, Arkansas, United States
Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.
- Conditions
- Breast Cancer Metastatic
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 847
- Registration Number
- NCT05155566
- Locations
- 🇦🇷
Pfizer country office, Buenos Aires, Argentina
🇬🇧Adelphi Mill, Bollington, Cheshire, SK10 5JB, UK, Bollington, Chesshire, United Kingdom
Real-world Treatment Patterns of Endocrine Based Therapy Among Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor-2-negative (HR+/HER2-) Advanced Breast Cancer: An Analysis of Administrative Claims Data in Japan
- Conditions
- Breast Cancer
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1170
- Registration Number
- NCT05153187
- Locations
- 🇯🇵
Pfizer Japan Inc., Tokyo, Japan
Lorlatinib Continuation Study
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 74
- Registration Number
- NCT05144997
- Locations
- 🇺🇸
UC Irvine Health, Orange, California, United States
🇨🇳The First affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 245
- Registration Number
- NCT05145127
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸Northwell Health HTC, New Hyde Park, New York, United States
🇺🇸Washington Institute for Coagulation d/b/a WACBD, Seattle, Washington, United States
Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 33
- Registration Number
- NCT05141708
- Locations
- 🇺🇸
Pfizer Inc., New York, New York, United States